Human Papillomavirus Infection
Conditions
Brief summary
This clinical trial studies how to improve the human papillomavirus (HPV) vaccination rate in young adults in Texas. This trial aims to learn more about how researchers and health care providers can increase HPV vaccination among college students.
Detailed description
PRIMARY OBJECTIVES: I. To determine the impact of addressing individual and system levels of influence on HPV vaccination initiation and completion rates. II. To gain insight into mechanisms of the intervention's efficacy, individual differences, and implementation of the intervention using mixed methods. OUTLINE: Participants are randomized to 1 of 6 groups. GROUP I: Participants receive standard Centers for Disease Control and Prevention (CDC) information about HPV vaccination. GROUP II: Participants receive video narratives about HPV vaccination. GROUP III: Participants receive written narratives about HPV vaccination. GROUP IV: Participants receive enhanced access to vaccination and standard CDC information about HPV vaccination. GROUP V: Participants receive enhanced access to vaccination and video narratives about HPV vaccination. GROUP VI: Participants receive enhanced access to vaccination and written narratives about HPV vaccination. After completion of study, participants are followed up at 3 and 9 months.
Interventions
OTHEREnhancing Accessibility to Health Care
Receive enhanced access to vaccination
OTHERInformational Intervention
Receive standard CDC information
OTHERInterview
Ancillary studies
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 26 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18-26 years. This criterion is based on the CDC recommendation of vaccination up to 26 years of age and the fact that individuals 18 years and older can consent by themselves for on-site vaccination * Ability to read and understand English * Self-identification as not yet having received any HPV vaccine injections. Self-identification is justified because it is safe to be vaccinated again, which could happen if a previously vaccinated person forgets their vaccination. Furthermore, in a person previously vaccinated with an older version of the vaccine, which targeted fewer HPV types, receiving the newer version would be advantageous and not cause any harm. Alternatives to self-identification, such as obtaining medical records from doctors' offices, would be very challenging for young adults, especially for those who do not remember when and where they might have received vaccination * Access to a smart phone, tablet or computer that is connected to the internet * Current enrollment in one of the participating schools with an anticipated continuous enrollment of at least 9 months
Exclusion criteria
* Being pregnant * Having a life-threatening allergy to any component of the HPV vaccine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rate of human papillomavirus (HPV) vaccination initiation | At 3 months |
| Rate of HPV vaccination completion | At 9 months |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORQian Lu, MD,PHD
M.D. Anderson Cancer Center
Outcome results
None listed